WebDoctor Encyclopedia

Cutaneous lymphomas Lymphomas

Adult T-cell leukaemia/lymphoma (ATLL)

Adult T-cell leukaemia/lymphoma (ATLL) is a rare T-cell cancer caused by long-term HTLV-1 infection. Its acute and lymphoma types are aggressive, while chronic and smouldering types grow slowly.

Medically reviewed Last reviewed October 21, 2026

What is adult T-cell leukaemia/lymphoma?

Adult T-cell leukaemia/lymphoma (ATLL) is a rare cancer of T lymphocytes, white blood cells that help control the immune system. It is caused by a long-term infection with a virus called human T-cell leukaemia virus type 1 (HTLV-1).

HTLV-1 is usually caught in early childhood through breastfeeding, or later through sex or blood. Most people with the virus never become ill. About 2-5% of carriers develop ATLL, usually many decades after infection.

The disease is most common where HTLV-1 is widespread: south-western Japan, the Caribbean, parts of South and Central America, sub-Saharan Africa, Iran and central Australia. In Europe it is mostly seen in people with family roots in these regions.

ATLL can behave in very different ways. The acute and lymphoma types grow quickly and are hard to treat. The chronic and smouldering types can stay stable for years.

Treatments include chemotherapy, antiviral therapy with zidovudine and interferon, the antibody mogamulizumab and donor stem cell transplant.

1. Key facts at a glance

Feature Details
Type of cancer Mature (peripheral) T-cell leukaemia/lymphoma
Cause Long-term HTLV-1 infection
How common Rare worldwide; about 1,000 new cases a year in Japan
Typical age Median about 65-70 in Japan; about 40-50 in the Caribbean and South America
Main sites Blood, lymph nodes, skin, liver, spleen, lungs, gut and bone
Typical blood finding “Flower cells”, T cells with lobed nuclei that look like petals
Common complications High calcium, serious infections
Main treatments Combination chemotherapy, zidovudine plus interferon alfa, mogamulizumab, donor stem cell transplant
Outlook Aggressive types: median survival about 8-12 months; indolent types: several years

2. Types of ATLL

Doctors use the Shimoyama classification, which has four types.

Type Share of cases Main features Behaviour
Acute About 55-60% High white count with flower cells, large lymph nodes, high calcium, organ involvement Aggressive
Lymphoma About 20-25% Mainly large lymph nodes; few abnormal cells in blood Aggressive
Chronic About 10-20% Raised lymphocyte count, sometimes skin, liver or lymph node involvement Indolent; “unfavourable” chronic type (high LDH, high urea or low albumin) behaves more like acute
Smouldering About 5-10% Few abnormal blood cells, often skin or lung lesions Indolent; may progress over years

3. Causes and risk factors

Factor Notes
HTLV-1 infection The essential cause. The virus inserts its genes into T cells and its proteins, Tax and HBZ, drive uncontrolled growth over decades
Infection early in life Infection through breastfeeding carries the highest lifetime risk of ATLL
High virus levels A high HTLV-1 proviral load in blood increases risk
Family history Clusters in families reflect shared infection, not inherited genes
Male sex and older age Slightly higher risk

How HTLV-1 spreads

Route Notes
Breastfeeding The main route for childhood infection; risk rises with longer breastfeeding
Sexual contact More often from men to women
Blood Transfusion of unscreened blood, or shared needles
Organ transplant Rare; donors are screened in many countries

Worldwide, an estimated 5-10 million people carry HTLV-1. Because infection is often silent, many carriers do not know they have it.

HTLV-1 also causes a nerve condition, HTLV-1-associated myelopathy (HAM/TSP), and an eye inflammation called uveitis.

4. How does it look?

4.1 On the body

Feature What it looks like
Skin Red patches, raised plaques, small bumps, larger nodules or a widespread red rash; seen in about half of patients
Lymph nodes Swollen, painless glands in the neck, armpits or groin
Abdomen Swelling from an enlarged liver or spleen
Jaundice Yellow skin or eyes if the liver is affected
Thin, unwell appearance In advanced disease

4.2 In blood tests and under the microscope

Feature What is seen
Flower cells Medium-sized T cells with deeply lobed, petal-like nuclei on the blood film
Markers CD3, CD4 and CD25 positive; CD7 often lost; CCR4 positive in most, which is the target of mogamulizumab
Lymph node or skin biopsy Sheets of abnormal T cells
HTLV-1 tests Antibodies in the blood; virus DNA integrated into tumour cells confirms ATLL

4.3 On scans

CT or PET-CT shows enlarged lymph nodes, liver or spleen, lung shadows and sometimes bone lesions. Scans help decide the type and plan treatment.

5. Symptoms

5.1 Common symptoms

Symptom Notes
Swollen glands Very common in acute and lymphoma types
Skin rash or lumps Can be the first sign, especially in smouldering type
Tiredness and weakness From the disease and anaemia
Fever, night sweats, weight loss Known as B symptoms
Abdominal fullness Enlarged liver or spleen
Cough or breathlessness Lung involvement or infection

5.2 Symptoms of high calcium

High blood calcium (hypercalcaemia) occurs in many people with acute ATLL and can be an emergency.

Symptom Notes
Thirst and passing a lot of urine Early signs
Constipation, nausea, vomiting Common
Confusion, drowsiness Need urgent treatment
Kidney problems From dehydration and calcium

5.3 Infections

ATLL weakens the immune system. Infections such as Pneumocystis pneumonia, cytomegalovirus, fungal infections and the worm Strongyloides are common and can be serious.

Strongyloides is a gut worm found in warm climates that can stay in the body for decades. In people with HTLV-1, and especially during steroid or chemotherapy treatment, it can multiply and spread through the body. For this reason, doctors test for it, or treat it with ivermectin, before starting cancer treatment.

5.4 When to see a doctor

People who know they carry HTLV-1, or who come from an area where it is common, should see a doctor for swollen glands, a persistent rash, fevers, sweats, weight loss or extreme thirst and confusion.

6. Diagnosis

Test Why it is done
Full blood count and blood film Looks for flower cells and raised lymphocytes
Flow cytometry Confirms CD4+ CD25+ abnormal T cells
HTLV-1 antibody test Confirms infection; positive results are checked with a second test
Biopsy Of a lymph node or skin lesion, to confirm lymphoma
Calcium, LDH, albumin, urea, kidney and liver tests Help define the type and outlook
CT or PET-CT Shows the extent of disease
Bone marrow biopsy In some cases
Infection screen Strongyloides, hepatitis B, HIV and others before treatment
Lumbar puncture For aggressive types, as ATLL can spread to the brain and spinal fluid

Conditions that can look similar

Condition How it differs
Mycosis fungoides and Sezary syndrome Skin T-cell lymphomas that can look almost identical in the skin and blood; HTLV-1 is negative
Peripheral T-cell lymphoma, not otherwise specified Similar under the microscope; no HTLV-1 integrated in the tumour cells
Chronic lymphocytic leukaemia A B-cell leukaemia with a high lymphocyte count; different markers
Reactive lymphocytosis Raised lymphocytes due to infection; cells are not clonal
HTLV-1 carrier state Some carriers have a few abnormal cells in the blood without ATLL; they are monitored

7. Treatment

Treatment depends mainly on the type of ATLL, the person’s age and fitness, and where they are treated. Approaches differ between Japan, where most research has been done, and Europe and the Americas, where antiviral therapy has a bigger role.

For aggressive types, the aim is to get the disease into remission quickly and then, if possible, proceed to a donor stem cell transplant. For indolent types, the aim is to control the disease with as little toxicity as possible.

7.1 Aggressive ATLL (acute, lymphoma, unfavourable chronic)

Treatment Notes
Combination chemotherapy In Japan, mLSG15 (VCAP-AMP-VECP) is standard; CHOP-like regimens are widely used elsewhere
Mogamulizumab An anti-CCR4 antibody, used first-line with chemotherapy in Japan and for relapse elsewhere
Brentuximab vedotin with CHP For CD30-positive disease
Zidovudine plus interferon alfa Antiviral therapy; works especially well in acute type, often combined with chemotherapy outside Japan
Allogeneic stem cell transplant For fit patients in remission; the only treatment offering long-term control for many
Brain protection Chemotherapy into the spinal fluid in selected patients

7.2 Indolent ATLL (smouldering, favourable chronic)

Option Notes
Watch and wait Common in Japan for patients without symptoms
Zidovudine plus interferon alfa Used in Europe and the Americas, with long-term disease control in many
Skin-directed therapy Creams, phototherapy or radiotherapy for skin lesions

7.3 Relapsed disease

Options include mogamulizumab, lenalidomide, valemetostat (approved in Japan), other chemotherapy and clinical trials.

7.4 Supportive care

Area What is done
Infection prevention Antibiotics against Pneumocystis, antifungal and antiviral medicines, treatment for Strongyloides
High calcium Intravenous fluids and bisphosphonates
Tumour lysis Fluids and medicines to protect the kidneys at the start of treatment

8. Side effects of treatment

Treatment Possible effects
Chemotherapy Low blood counts, infections, hair loss, nausea
Mogamulizumab Infusion reactions, skin rashes (sometimes severe); raises the risk of graft-versus-host disease if given shortly before transplant
Zidovudine Anaemia, nausea
Interferon alfa Flu-like symptoms, tiredness, low mood
Stem cell transplant Graft-versus-host disease, infections, organ damage

9. Outlook

Type Approximate 4-year survival (large Japanese series)
Acute About 10-15%
Lymphoma About 15-20%
Chronic About 35-40%
Smouldering About 50-60%

The outlook also depends on age, calcium and LDH levels, and the general health of the patient. Prognostic indexes, such as the ATL-PI, combine these to estimate risk.

Outcomes are improving with mogamulizumab and transplant. About a third of patients who undergo donor transplant are alive in long-term remission.

10. Prevention

ATLL can be prevented by stopping the spread of HTLV-1.

  • Antenatal screening and advice to avoid or shorten breastfeeding for mothers who carry the virus
  • Screening of blood and organ donors
  • Condoms and safer sex
  • Never sharing needles

11. Living with ATLL

ATLL and its treatment place a heavy burden on patients and families. Specialist lymphoma teams, nurses and social workers help with treatment decisions, symptom control and practical needs.

Family members may wish to be tested for HTLV-1. A positive test is not a diagnosis of cancer, and most carriers stay well for life.

Carriers do not usually need treatment. Some specialist centres offer regular check-ups with blood counts and skin examinations, especially for people with a high viral load. Carriers should not donate blood, organs or breast milk, and pregnant carriers can get advice about feeding their baby safely.

12. Frequently asked questions

Question Answer
Is ATLL contagious? The cancer itself is not, but HTLV-1 can pass through breastfeeding, sex and blood
If I carry HTLV-1, will I get ATLL? Most carriers never do; the lifetime risk is about 2-5%
Is it related to HIV? Both are retroviruses, but they are different viruses with different diseases
Can it be cured? Some patients achieve long-term remission after donor transplant; for others treatment aims at control
Should my children be tested? Ask your doctor; testing is often offered to family members

13. Questions to ask your care team

  • Which type of ATLL do I have, and is it aggressive or indolent?
  • What are the aims of treatment: cure, long-term control or symptom relief?
  • Am I a candidate for a donor stem cell transplant, and should my siblings be tested as donors?
  • Would zidovudine and interferon or mogamulizumab be suitable for me?
  • What can I do to lower my risk of infection?
  • Should my partner, children or other family members be tested for HTLV-1?

Resources

  1. Shimoyama, M. (1991) ‘Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)’, British Journal of Haematology, 79(3), pp. 428-437.
  2. Ishitsuka, K. and Tamura, K. (2014) ‘Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma’, The Lancet Oncology, 15(11), pp. e517-e526.
  3. Cook, L.B. et al. (2019) ‘Revised adult T-cell leukemia-lymphoma international consensus meeting report’, Journal of Clinical Oncology, 37(8), pp. 677-687.
  4. Tsukasaki, K. et al. (2007) ‘VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801’, Journal of Clinical Oncology, 25(34), pp. 5458-5464.
  5. Bazarbachi, A. et al. (2010) ‘Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes’, Journal of Clinical Oncology, 28(27), pp. 4177-4183.
  6. Katsuya, H. et al. (2015) ‘Treatment and survival among 1594 patients with ATL’, Blood, 126(24), pp. 2570-2577.
  7. Phillips, A.A. et al. (2019) ‘Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma’, Haematologica, 104(5), pp. 993-1003.
  8. Ishida, T. et al. (2017) ‘Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies’, Cancer Science, 108(10), pp. 2022-2029.

Prepared by the editorial team, October 2026.